Celsion Co. (NASDAQ:CLSN) shares fell 5.8% during trading on Thursday . The company traded as low as $0.70 and last traded at $0.71. 1,333,150 shares changed hands during mid-day trading, a decline of 19% from the average session volume of 1,640,737 shares. The stock had previously closed at $0.75.
A number of research analysts have recently weighed in on CLSN shares. Zacks Investment Research downgraded Celsion from a “hold” rating to a “sell” rating in a research note on Wednesday, December 23rd. ValuEngine raised Celsion from a “hold” rating to a “buy” rating in a research note on Tuesday, December 1st.
The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.67 and a current ratio of 3.67. The company has a 50 day moving average of $0.63 and a 200 day moving average of $1.26.
A number of institutional investors have recently modified their holdings of the stock. Two Sigma Advisers LP acquired a new stake in Celsion during the 2nd quarter worth $49,000. Charles Schwab Investment Management Inc. bought a new position in Celsion during the 2nd quarter worth about $64,000. Eudaimonia Partners LLC increased its holdings in Celsion by 23.5% during the 3rd quarter. Eudaimonia Partners LLC now owns 105,000 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 20,000 shares in the last quarter. Jane Street Group LLC bought a new position in Celsion during the 3rd quarter worth about $34,000. Finally, GSA Capital Partners LLP bought a new position in Celsion during the 3rd quarter worth about $115,000. 11.41% of the stock is currently owned by institutional investors and hedge funds.
Celsion Company Profile (NASDAQ:CLSN)
Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.
Read More: How to invest in blue-chip stocks
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.